Cargando…
p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL
Deletion of the short-arm of chromosome 17 (17p-) is one of the most critical genetic alterations used in chronic lymphocytic leukemia (CLL) risk stratification. The tumor suppressor TP53 maps to this region, and its loss or mutation accelerates CLL progression, hampers response to chemotherapy and...
Autores principales: | Lee, H J, Gallardo, M, Ma, H, Zhang, X, Larsson, C A, Mejia, A, Hornbaker, M J, Qi, Y, Su, X, Pageon, L R, Quintas-Cardama, A, Post, S M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5141356/ https://www.ncbi.nlm.nih.gov/pubmed/27284738 http://dx.doi.org/10.1038/bcj.2016.41 |
Ejemplares similares
-
p53 pathway dysfunction in AML: beyond TP53 mutations
por: Post, Sean M., et al.
Publicado: (2017) -
CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness
por: Lewis, Richard, et al.
Publicado: (2021) -
Ibrutinib dose modifications in the management of CLL
por: Hardy-Abeloos, Camille, et al.
Publicado: (2020) -
AID Contributes to Accelerated Disease Progression in the TCL1 Mouse Transplant Model for CLL
por: Schubert, Maria, et al.
Publicado: (2021) -
HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model
por: Maharaj, Kamira, et al.
Publicado: (2020)